EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk of metastasis in BRCA2 carriers diagnosed with triple‐negative breast cancer

Marcelo Moreno iD, Júlia Salles Oliveira iD, Rafael Canfield Brianese iD, Douglas Guedes de Castro iD, Solange Moraes Sanches iD, Giovana Tardin Torrezan iD, Karina Miranda Santiago iD, Marina De Brot iD, Vladmir Claudio Cordeiro de Lima iD, Fabiana Baroni Alves Makdissi iD, Jose Claudio Casali Da Rocha iD, Vinicius Fernando Calsavara iD und 1 weitere

Cancer Medicine · 2023-08 · 12 (15) · 16129-16141

DOI: 10.1002/cam4.6267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 23.07.2023. Verfasst von Marcelo Moreno und 12 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program of A.C. Camargo Cancer Center, São Paulo, Brazil. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple‐negative breast cancer (TNBC) is the neoplasia most associated with BRCA1 germline pathogenic variants (PV) and is more likely to develop metastases than the other breast cancer (BC) subtypes, mainly in the lungs and the central nervous system (CNS). Recently, BRCA2 carriers were shown to have a higher risk for developing CNS metastases. However, the patterns of recurrence and metastases of BRCA2 carriers with TNBC are unknown.

Methods

TNBC patient data attending the A.C. Camargo Cancer Center, from 1998 through 2020, were verified either by medical records or by BRCA1/2 genetic testing carried out. Multivariable logistic regression models were fit to the data to assess the independent factors for bone and CNS metastases. Adjustment was done using all independent variables with p < 0.2 in the univariable Cox model to describe the relationship between the independent variables until time of death.

Results

A total of 388 TNBC patients were evaluated. We identified PV in BRCA1/2 genes in 21% (82/388), being 17.7% (69/388) in BRCA1 and only 3.3% (13/388) in BRCA2 . A total of 120 patients (31%) developed distant metastases. Bone or CNS metastases were observed in 40% and 60% of BRCA2 PV carriers ( p = 0.155), respectively. The BRCA2 carriers tended to have a higher likelihood of developing bone metastases (OR, 4.06; 95% CI, 0.82–20.01; p = 0.085), when compared to BRCA1 carriers (OR, 0.6; 95% CI, 0.12–2.87; p = 0.528). BRCA2 carriers had an OR of 1.75 (95% CI, 0.33–9.14; p = 0.503) for CNS metastasis development, while BRCA1 carriers had an OR of 0.72 (95% CI, 0.23–2.23; p = 0.574).

Conclusions

Patients with TNBC and PV in the BRCA2 gene had higher frequencies of secondary bone involvement and CNS in the course of the disease. However, the BRCA2 PV did not represent an independent outcome predictor of metastases and overall survival. Efforts to increase the number of BRCA2 carriers among TNBC patients are crucial for determining their risk of developing bone and CNS metastases compared to BRCA2 noncarriers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsTriple Negative Breast NeoplasmsFemaleHumansBRCA1 ProteinBRCA2 ProteinGenes, BRCA2Genetic Predisposition to Disease

Stichwörter der Autor:innen

BRCA mutationsBRCA1 geneBRCA2 genebreast cancermetastasis

Substanzen

BRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Graduate Program of A.C. Camargo Cancer Center, São Paulo, Brazil.
  • Medicine Course and Biomedical Sciences, Federal University of Fronteira Sul, Chapecó, Santa Catarina, Brazil.
  • Clinical and Functional Genomics Group, CIPE, A.C. Camargo Cancer Center, São Paulo, Brazil.
  • Department of Radiation Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil.
  • Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil.
  • National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation (INCITO), São Paulo, Brazil.

ORCID-Profile: Marcelo Moreno, Júlia Salles Oliveira, Rafael Canfield Brianese, Douglas Guedes de Castro, Solange Moraes Sanches, Giovana Tardin Torrezan, Karina Miranda Santiago, Marina De Brot, Vladmir Claudio Cordeiro de Lima, Fabiana Baroni Alves Makdissi, Jose Claudio Casali Da Rocha, Vinicius Fernando Calsavara, Dirce Maria Carraro

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Moreno, M., Oliveira, J. S., Brianese, R. C., de Castro, D. G., Sanches, S. M., Torrezan, G. T., Santiago, K. M., De Brot, M., Cordeiro de Lima, V. C., Baroni Alves Makdissi, F., Casali Da Rocha, J. C., Calsavara, V. F., & Carraro, D. M. (2023). Risk of metastasis in BRCA2 carriers diagnosed with triple‐negative breast cancer. Cancer Medicine, 12(15), 16129-16141. https://doi.org/10.1002/cam4.6267

Vancouver

Moreno M, Oliveira JS, Brianese RC, de Castro DG, Sanches SM, Torrezan GT, et al. Risk of metastasis in BRCA2 carriers diagnosed with triple‐negative breast cancer. Cancer Medicine. 2023;12(15):16129-16141. doi:10.1002/cam4.6267

BibTeX
@article{Moreno2023,
  author = {Moreno, Marcelo and Oliveira, Júlia Salles and Brianese, Rafael Canfield and de Castro, Douglas Guedes and Sanches, Solange Moraes and Torrezan, Giovana Tardin and Santiago, Karina Miranda and De Brot, Marina and Cordeiro de Lima, Vladmir Claudio and Baroni Alves Makdissi, Fabiana and Casali Da Rocha, Jose Claudio and Calsavara, Vinicius Fernando and Carraro, Dirce Maria},
  title = {Risk of metastasis in BRCA2 carriers diagnosed with triple‐negative breast cancer},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {15},
  pages = {16129--16141},
  doi = {10.1002/cam4.6267}
}
Kostenlos starten →